BMRN - BIOMARIN PHARMACEUTICAL INC

QQQ $ 473.83 $ -2.14 (-0.45 %)

DIA $ 417.12 $ -0.26 (-0.06 %)

SPY $ 563.14 $ 0.30 (0.05 %)

TLT $ 100.82 $ -0.51 (-0.5 %)

GLD $ 237.35 $ -1.31 (-0.55 %)

Previous Close

$ 69.86

Open

$ 69.98

Bid

$ 70.52 x 100

Ask

-- x --

Day's Range

$ 68.93 - $ 71.63

52 Week Range

$ 69.60 - $ 99.56

Volume

10,579,579

Average Volume

Market Cap

13.3B

Beta (5Y Monthly)

$ 0.67

PE Ratio (TTM)

$ 51.83

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-05-2024	06-30-2024	10-Q
2	04-26-2024	03-31-2024	10-Q
3	02-26-2024	12-31-2023	10-K
4	11-02-2023	09-30-2023	10-Q
5	08-02-2023	06-30-2023	10-Q
6	04-28-2023	03-31-2023	10-Q
7	02-27-2023	12-31-2022	10-K
8	10-28-2022	09-30-2022	10-Q
9	08-04-2022	06-30-2022	10-Q
10	04-29-2022	03-31-2022	10-Q
11	02-25-2022	12-31-2021	10-K
12	10-29-2021	09-30-2021	10-Q
13	07-30-2021	06-30-2021	10-Q
14	04-30-2021	03-31-2021	10-Q
15	02-26-2021	12-31-2020	10-K
16	11-06-2020	09-30-2020	10-Q
17	08-05-2020	06-30-2020	10-Q
18	05-01-2020	03-31-2020	10-Q
19	02-27-2020	12-31-2019	10-K
20	10-29-2019	09-30-2019	10-Q
21	08-02-2019	06-30-2019	10-Q
22	04-29-2019	03-31-2019	10-Q
23	02-28-2019	12-31-2018	10-K
24	10-26-2018	09-30-2018	10-Q
25	08-03-2018	06-30-2018	10-Q
26	04-27-2018	03-31-2018	10-Q
27	02-26-2018	12-31-2017	10-K
28	10-31-2017	09-30-2017	10-Q
29	08-02-2017	06-30-2017	10-Q
30	05-04-2017	03-31-2017	10-Q
31	02-27-2017	12-31-2016	10-K
32	11-03-2016	09-30-2016	10-Q
33	08-08-2016	06-30-2016	10-Q
34	05-02-2016	03-31-2016	10-Q
35	02-29-2016	12-31-2015	10-K
36	11-02-2015	09-30-2015	10-Q
37	08-05-2015	06-30-2015	10-Q
38	05-05-2015	03-31-2015	10-Q
39	03-02-2015	12-31-2014	10-K
40	10-28-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Scotiabank Maintains Sector Perform on Bio...
09/17/2024 15:25:36

Scotiabank analyst George Farmer maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and lowers the price ...

Truist Securities Maintains Buy on Biomari...
09/17/2024 14:39:24

Truist Securities analyst Joon Lee maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target fr...

Wells Fargo Maintains Overweight on Biomar...
09/17/2024 14:10:52

Wells Fargo analyst Mohit Bansal maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price targ...

RBC Capital Maintains Sector Perform on Bi...
09/17/2024 14:01:30

RBC Capital analyst Luca Issi maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and lowers the price tar...

ge-vernova-to-rally-over-30-here-are-10-top-analyst-forecasts-for-tuesday

GE Vernova To Rally Over 30%? Here Are 10 ...
09/17/2024 13:00:39

B of A Securities Maintains Buy on Biomari...
09/17/2024 12:21:15

B of A Securities analyst Geoff Meacham maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price targ...

Stifel Maintains Buy on Biomarin Pharmaceu...
09/17/2024 12:03:42

Stifel analyst Paul Matteis maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target from $115...

Bernstein Maintains Outperform on Biomarin...
09/17/2024 11:54:01

Bernstein analyst William Pickering maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and lowers the price t...

despite-being-first-mover-biomarins-voxzogo-for-dwarfism-to-face-pressure-from-ascendis-candidate-in-near-term

Despite Being First Mover, BioMarin's Voxz...
09/16/2024 19:12:28

BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by l...

Canaccord Genuity Maintains Hold on Biomar...
09/13/2024 18:08:20

Canaccord Genuity analyst Whitney Ijem maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Hold and maintains $93 price t...

bmrn---analyzing-biomarin-pharmaceuticals-short-interest

(BMRN) - Analyzing Biomarin Pharmaceutical...
09/10/2024 14:15:21

Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:32:45

Cantor Fitzgerald analyst Olivia Brayer reiterates Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $11...

fda-battles-backlog-of-drug-factory-inspections-since-covid-19

FDA Battles Backlog of Drug Factory Inspec...
09/06/2024 15:52:51

FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.

JP Morgan Maintains Overweight on Biomarin...
09/05/2024 16:05:09

JP Morgan analyst Jessica Fye maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target ...

RBC Capital Reiterates Sector Perform on B...
09/05/2024 15:56:19

RBC Capital analyst Luca Issi reiterates Biomarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and maintains $100 pric...

Scotiabank Maintains Sector Perform on Bio...
09/05/2024 15:14:12

Scotiabank analyst George Farmer maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and raises the price ...

biomarin-restructures-outlines-roadmap-to-4b-revenues-by-2027

BioMarin Restructures, Outlines Roadmap To...
09/05/2024 13:51:16

BioMarin aims for $4 billion revenue by 2027, focusing on gene therapy and enzyme treatments, with a robust pipeline set to enh...

Piper Sandler Maintains Overweight on Biom...
09/05/2024 13:45:53

Piper Sandler analyst Christopher Raymond maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the p...

Deep Dive Into Biomarin Pharmaceutical Sto...
09/05/2024 13:00:53

Truist Securities Maintains Buy on Biomari...
09/05/2024 12:12:54

Truist Securities analyst Robyn Karnauskas maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price t...

6 Gene Therapy M&A Targets On The Radar
03/27/2019 16:45:40